Table 2.
Current ongoing phase II and III trials with key selective FGFR tyrosine kinase inhibitors
| Agent and study ID | Phase | Indication | Regimen | No. of patients |
|---|---|---|---|---|
| Infigratinib (BGJ398) | ||||
| NCT03773302 | III | Cholangiocarcinoma | Infigratinib vs. gemcitabine/cisplatin | 384 |
| NCT04197986 | III | Urothelial cancer | Infigratinib vs. placebo | 218 |
| NCT02150967 | II | Cholangiocarcinoma | Infigratinib | 160 |
| NCT04233567 | II | Solid tumors | Infigratinib | 50 |
| Pemigatinib (INCB054828) | ||||
| NCT02872714 (FIGHT‐201) | II | Urothelial cancer | Pemigatinib | 240 |
| NCT04003610 (FIGHT‐205) | II | Urothelial cancer | Pemigatinib + pembrolizumab vs. pemigatinib vs. standard of care | 378 |
| NCT03914794 | II | Urothelial cancer | Pemigatinib | 43 |
| NCT03822117 (FIGHT‐207) | II | Solid tumors | Pemigatinib | 170 |
| NCT03011372 (FIGHT‐203) | II | Myeloproliferative neoplasms | Pemigatinib | 46 |
| NCT02924376 (FIGHT‐202) | II | Cholangiocarcinoma | Pemigatinib | 140 |
| NCT03656536 (FIGHT‐302) | III | Cholangiocarcinoma | Pemigatinib vs. gemcitabine/cisplatin | 432 |
| NCT04256980 | II | Cholangiocarcinoma | Pemigatinib | 54 |
| NCT04003623 | II | Solid tumors | Pemigatinib | 50 |
| NCT02393248 (FIGHT‐101) | I/II | Solid tumors | Pemigatinib; combination therapy | 325 |
| Derazantinib (ARQ 087) | ||||
| NCT03230318 | II | Cholangiocarcinoma | Derazantinib | 143 |
| NCT04045613 | Ib/II | Urothelial cancer | Derazantinib vs. derazantinib + atezolizumab | 303 |
| Futibatinib (TAS‐120) | ||||
| NCT04024436 | II | Breast cancer | Futibatinib or futibatinib + fulvestrant | 168 |
| NCT02052778 | I/II | Solid tumors | Futibatinib | 371 |
| Erdafitinib (JNJ‐42756493) | ||||
| NCT03390504 | III | Urothelial cancer | Erdafitinib vs. vinflunine or docetaxel or pembrolizumab | 631 |
| NCT03210714 | II | Solid tumors, non‐Hodgkin lymphoma, or histiocytic disorders | Erdafitinib | 49 (age >21 years) |
| NCT04083976 | II | Solid tumors | Erdafitinib | 280 |
| NCT02699606 | II | Urothelial cancer | Erdafitinib | 63 (Asian) |
| NCT03827850 (FIND) | II | NSCLC | Erdafitinib | 50 |
| NCT02365597 | II | Urothelial cancer | Erdafitinib | 217 |
| NCT02952573 | II | Multiple myeloma | Erdafitinib | 20 |
| NCT03999515 | II | Prostate cancer | Erdafitinib + abiraterone acetate or enzalutamide | 25 |
| NCT04172675 | II | Urothelial cancer | Erdafitinib vs. investigator choice intravesical chemotherapy | 280 |
| NCT03473743 | I/II | Urothelial cancer | Erdafitinib in combination with cetrelimab and/or platinum | 160 |
Abbreviations: FGFR, fibroblast growth factor receptor; NSCLC, non‐small cell lung cancer.